Launch week offerEnds in00h00m00s

annual Promonthly Pro

Marco Valgimigli

Professor of Medicine

Università della Svizzera italiana Facoltà di scienze biomediche

Switzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Switzerland

About

Marco Valgimigli is a Professor of Medicine at Università della Svizzera italiana Facoltà di scienze biomediche, Switzerland. His research interests focus on cardiovascular interventions, antithrombotic therapy, and risk stratification in patients with coronary conditions. Recent publications include studies on antiplatelet strategies, bleeding risk assessment, and innovative techniques for coronary interventions.

Articles (27)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (20)

Sunil V. Rao

UNITED STATES

Marco Valgimigli

Research Interests

Make your next move.

Explore related searches

About

Articles (27)

Ethnicity does not equal region and patient-level evidence should always prevail over aggregate-data inference: the treatment effects of clopidogrel are consistent across Asian and non-Asian regions of enrolment

Clinical Management of Myocardial Infarction

Response by Leonardi et al to Letter Regarding Article, “Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome”

Great debate: clopidogrel should now replace aspirin for long-term secondary prevention of coronary artery disease

Impact of guidelines-directed very-high-risk criteria in the identification and management of occlusion myocardial infarction in patients with NSTE-ACS

Radial access for percutaneous coronary intervention: the good, the better, and the ugly

Novel Global Platelet Reactivity Biomarker for a More Precise Ischemic Risk Stratification

Antithrombotic therapy in patients with chronic coronary syndrome: a focus on the 2024 European Society of Cardiology guidelines

Swinging Pendulum Between Risks and Benefits of Antiplatelet Agents: A Call for Consistency in the Interpretation of Evidence and Guideline Recommendations

Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?

Validation of the Mayo Clinic Percutaneous Coronary Intervention Risk Prediction Score in Patients With Acute Coronary Syndrome

Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution

Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome

Comparison of 1-month vs. 12-month dual antiplatelet therapy after implantation of drug-eluting stents in patients with acute coronary syndrome: the ULTIMATE-DAPT trial

Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction: The PiCSO-AMI-I Trial

Risk Burden of Cancer in Patients Treated With Abbreviated Dual Antiplatelet Therapy After PCI: Analysis of Multicenter Controlled High-Bleeding Risk Trials

Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial

Vascular Access in Percutaneous Coronary Intervention of Chronic Total Occlusions: A State-of-the-Art Review

Antithrombotic therapy in patients with established atherosclerotic coronary disease

Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled trials

Sailing in the complexity of the ‘shark-fin’ sign

Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials

Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis

Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge

Not only lungs: COVID-19 hits platelets as well

Management of acute coronary syndromes in older adults

Collaborators (20)

Sunil V. Rao

Dan Atar

Francesco Costa

Felice Gragnano

Victor Aboyans

Diana Gorog

henning kelbæk

Arnoud van 't Hof

Robert Storey

Lukas Hunziker

Dominick Joseph Angiolillo

Sergio Leonardi

Daniele Giacoppo

C Berry

David Erlinge

Adnan Kastrati

Neil O'Leary

Vijay Kunadian

Gabor Toth G

Azfar Ghaus Zaman

Make your next move.